Under the agreement, Amedica/US Spine will distribute BioDlogics’ stem cell products for spinal fusion, adhesion barrier and nerve protection. Ben Shappley, president and CEO of Amedica/US Spine, says the agreement will increase the company’s presence in the biologic market and complements the line of MC2 Silicon Nitride spine spacers it already offers.
The BioDfence and BioDfactor products are packaged at an FDA-registered tissue bank.
Read more about the agreement between Amedica/US Spine and BioDlogics.
Read more about Amedica/US Spine:
– Amedica Acquires US Spine
– Amedica Patents Motion-Preserving Spine Implant
– Amedica Receives Patent for Knee Prosthesis
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
